Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Methods Mol Biol. 2018;1827:367–380. doi: 10.1007/978-1-4939-8648-4_19

Fig. 2.

Fig. 2

LC-ESI-MS analysis of intact Herceptin and the deglycosylated Herceptin. (a) Intact commercial Herceptin; (b) Deglycosylated Herceptin (Fucα1,6GlcNAc-Herceptin, F2-Herceptin) obtained from Endo-S2 treatment